Zimmer Biomet stock holds steady after dividend update and restructuring news

Zimmer Biomet stock (ISIN US98956P1021) closed at USD 95.36 on September 18, 2026 on the New York Stock Exchange, leaving the medical device group about 10.8 percent below its 52-week high of USD 106.88 and 20.5 percent above the 52-week low of USD 79.12.

Dated dividend signal and yield

According to an article on Zimmer Biomet from a German financial portal dated September 20, 2026, the company confirmed a cash dividend of USD 0.24 per share with an ex-dividend date set for September 30, 2026, and a forward annualized payout of USD 0.96 per share based on four quarterly distributions.

The same overview calculated that, on the September 18, 2026 closing price of USD 95.36, this forward dividend would correspond to a yield of around 1.02 percent, giving investors a modest income component alongside the stock’s capital performance.

Market metrics and comparative valuation

Price data compiled by equity portals show Zimmer Biomet shares most recently traded at USD 95.36, with a daily change of plus 1.18 percent versus the prior close, for a one-day gain that leaves the stock mid-range within its intraday band of roughly USD 93.71 to USD 96.16 as of September 18, 2026.

Market capitalization snapshots from Nasdaq-based aggregators put Zimmer Biomet’s equity value at approximately USD 18.18 billion as of September 18, 2026, implying that the stock’s 1.11 percent market cap increase in 2026 to that level has roughly matched the share price gain recorded in the same period.

Restructuring moves and Swiss job cuts

Beyond shareholder distributions, Zimmer Biomet has also been in the spotlight for restructuring at its Swiss operations: a report in the Swiss press on September 10, 2026 stated that the company plans to cut 580 jobs at its Winterthur site as part of a reorganization of its manufacturing footprint, highlighting cost and efficiency pressures alongside the dividend stability.

For investors, the combination of a confirmed dividend and a sizeable job reduction illustrates how Zimmer Biomet is trying to balance returning cash to shareholders with streamlining operations to protect margins, although the Swiss restructuring could entail short-term costs and social sensitivities in the region.

Stock level and investor perspective

Zimmer Biomet stock thus remains below its 52-week peak at USD 106.88, but clearly above the 52-week low of USD 79.12, with a market capitalization of about USD 18.18 billion as of September 18, 2026 and a forward dividend yield near 1 percent providing a measured blend of income and potential price recovery.

More news and analyses on Zimmer Biomet stock